Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT01898845 Completed - Clinical trials for Advanced Solid Tumors

A Phase I Study of LEE011 in Asian Patients

Start date: May 2013
Phase: Phase 1
Study type: Interventional

This study will evaluate safety and tolerability to estimate the MTD and/or recommended dose for expansion.

NCT ID: NCT01898078 Completed - Lymphoma Clinical Trials

Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas

Start date: July 16, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of food on the single-dose pharmacokinetics (PK) of alisertib administered as an enteric-coated tablet (ECT) formulation in participants with advanced solid tumors or lymphomas.

NCT ID: NCT01867866 Completed - Clinical trials for Advanced Solid Tumors

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

Start date: May 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to compare the pharmacokinetics of trifluorothymidine (FTD) as a component of TAS-102 with FTD alone.

NCT ID: NCT01867073 Active, not recruiting - Clinical trials for Advanced Solid Tumors

A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours

Start date: May 2011
Phase: N/A
Study type: Observational

OPB-51602 is a novel oral small molecule STAT3 inhibitor developed by Otsuka Pharmaceutical Company, Ltd, and is currently undergoing clinical investigation at the National University Health System (NUHS), Singapore. The proposed correlative pharmacodynamic and pharmacogenetic biomarker study is initiated and funded by the investigators, and will be conducted in conjunction with the extension phase I protocol of OPB-51602 in patients with advanced solid tumours (Study code 266-09-801-01/ DSRB protocol B/09/514). All biomarker and pharmacogenetic samples will be collected, stored and analysed at the local laboratory of the study site (Cancer Science Institute, National University Health System, Singapore, Dr Boon-Cher Goh).

NCT ID: NCT01847118 Recruiting - Clinical trials for Advanced Solid Tumors

A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors

Start date: April 2013
Phase: Phase 1
Study type: Interventional

This study is to assess the safety, tolerability and pharmacokinetics of single dose and multiple doses of humanized anti-VEGF monoclonal antibody (Sevacizumab) in patients with advanced or metastatic solid tumors. The secondary objective is to explore the preliminary anti-tumor effects.

NCT ID: NCT01830816 Completed - Multiple Myeloma Clinical Trials

Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Start date: September 16, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the single-dose pharmacokinetic (PK) parameters of ixazomib (MLN9708) in cancer participants with either normal renal function or severe renal impairment (RI), including participants with end-stage renal disease (ESRD).

NCT ID: NCT01781429 Completed - Clinical trials for Advanced Solid Tumors

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Start date: March 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This open-label, multi-center Phase 1/2 study will assess the safety, pharmacokinetics, and pharmacodynamics of escalating doses of BVD-523 in patients with advanced malignancies. The study also seeks to demonstrate target modulation and early signs of clinical response in select patient populations.

NCT ID: NCT01773421 Completed - Clinical trials for Advanced Solid Tumors

An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors

Start date: June 30, 2011
Phase: Phase 1
Study type: Interventional

This study consists of two Parts. Part A (Food Effect Study) and Part B (Determination of Maximum Tolerated Dose [MTD] for twice daily [BID] Dosing).Part A will be initiated first, and Part B will be initiated after the PK results of Part A have been evaluated.

NCT ID: NCT01723020 Completed - Cancer Clinical Trials

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

Start date: December 27, 2012
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma

NCT ID: NCT01714947 Completed - Lymphoma Clinical Trials

Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib

Start date: January 24, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the mass balance (i.e. cumulative excretion of total radioactivity [TRA] in urine and feces) of alisertib and pharmacokinetic (PK) of alisertib in plasma and urine, and of TRA in plasma and whole blood.